

# **UNIVERSITI PUTRA MALAYSIA**

MECHANISM OF THE ANTI-INFLAMMATORY ACTION OF 3-(2-HYDROXY-PHENYL)-1-(5-METHYL-FURAN-2-Y-L) PROPENONE (HMP)

**LIEW CHOI YI** 

FPSK(m) 2010 13

# MECHANISM OF THE ANTI-INFLAMMATORY ACTION OF 3-(2-HYDROXY-PHENYL)-1-(5-METHYL-FURAN-2-Y-L) PROPENONE (HMP)



Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Master of Science Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

**MECHANISM OF THE ANTI-INFLAMMATORY ACTION OF 3-(2-**HYDROXY-PHENYL)-1-(5-METHYL-FURAN-2-Y-L) PROPENONE (HMP)

Bv

LIEW CHOI YI

**July 2010** 

Chairman: Professor Daud Ahmad bin Israf Ali, PhD

**Faculty: Medical and Health Sciences** 

Chalcones, a subgroup of flavonoids, are found in many plants and many synthetic analogues have been artificially synthesized. Many natural and synthetic chalcones exhibit varying degress of anti-inflammatory activity. In an attempt to discover more potent anti-inflammatory compounds, 3-(2-hydroxyphenyl)-1-(5-methyl-furan-2-y-l) propenone (HMP) was evaluated for its ability to inhibit the synthesis of major proinflammatory mediators and cytokines in interferon-y  $(IFN-\gamma)$ lipopolysaccharide (LPS)-induced RAW 264.7 cells and phorbol myristate acetate (PMA)-differentiated/LPS-induced U937 cells in study I, II, III and IV respectively. The 96-well plate assays included cell viability test, griess, chemical scavenging assay and enzyme-linked immunosorbent assays were conducted meanwhile western blotting, reverse transcription-polymerase chain reactions, immunoprecipitation, kinase assay, electrophoretic mobility shift assay and docking experiment were applied for molecular detection throughout the studies. In study I, II and III, HMP suppressed the production of nitric oxide (NO) at doses as low as 0.78 µM, prostaglandin E2 (PGE2) and interleukin (IL)-1β secretion at doses of 12.5 μM and above meanwhile tumor necrosis factor (TNF)- $\alpha$  and IL-6 secretion at 25  $\mu$ M with significant inhibitory effects (p < 0.05). HMP did not affect the secretion of chemokines IL-8 and monocyte chemotactic protein-1 (MCP-1) and the anti-inflammatory cytokine IL-10. HMP showed a dosedependent inhibition of NO synthesis as demonstrated from NO secretion and inducible nitic oxide synthase (iNOS) expression. For study III and IV in which western blotting and kinase assay were conducted, the inhibition of NO synthesis was related to the inhibition of p38 phosphorylation and potent inhibition of p38 kinase activity that led to significant inhibition of phosphorylation of activating transcription factor (ATF)-2. This effect in turn caused significant inhibition of activating protein (AP)-1-DNA binding which partially explains the inhibitory effect upon the synthesis of iNOS. Interestingly, HMP failed to alter phosphorylation of extracellular-signal-related-kinase (ERK) 1/2 and Jun N-terminal kinase (JNK) and did not affect their kinase activity. Furthermore, HMP also failed to inhibit phosphorylation of Inhibitory protein  $\kappa B$  (I- $\kappa B$ ), nuclear translocation of p65 nuclear factor-κB (NF-κB) and DNA binding of p65 NF-κB. Phosphorylation of signal transducers and activators of transcription (STAT)-1 was also unaffected by HMP. Molecular docking experiments confirmed that HMP fits well in the highly conserved hydrophobic pocket of p38 MAP kinase. In conclusion, in contrast to many anti-inflammatory chalcones, HMP shows a higher selectivity toward NO inhibition therefore providing an interesting drug lead that has potentially less side effects.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

MEKANISME ANTI-RADANG 3-(2-HYDROXY-PHENYL)-1-(5-METHYL-FURAN-2-Y-L) PROPENONE (HMP)

Oleh

**LIEW CHOI YI** 

**Julai 2010** 

Pengerusi: Profesor Daud Ahmad bin Israf Ali, PhD

Fakulti: Perubatan dan Sain Kesihatan

Calkon, sejenis subkelompok flavonoid, diterima dalam banyak tumbuhan telah dihasilkan dalam bentuk analog sintetik. Kebanyakan calkon semula jadi ataupun analog sintetik menunjukkan pelbagai darjah aktiviti anti-radang. Untuk menemui lebih banyak anti-radang *compound*, keupayaan 3-(2-hidroksi-fenil)-1-(5-metil-furan-2-il) propenone (HMP) telah dikaji untuk menghalang mediator pro-inflamasi dan sitokin yang dihasilkan daripada induksi oleh interferon (IFN)-γ dan lipopolisakarida (LPS) dalam sel- sel RAW264.7 dan juga induksi oleh LPS dalam sel-sel U937 yang telah ditransformasi oleh forbol miristat asetat (PMA) dalam kajian I, II, III dan IV masingmasing. Ujian-ujian 96-well plate dimana termasuknya kajian tentang kebolehhidupan sel, *griess*, *chemical scavenging* dan asai imunoserapan terangkai enzim telah digunakan. Western blotting, tindak balas rantaian reverse transcription-polymerase, pengimunomendakan, ujian kinase, ujian syif kegerakan elektroforesis dan eksperimen

docking juga digunakan dalam keseluruhan projek ini. HMP dapat menghalang pengeluaran oksida nitrik (NO) pada dos serendah 0.78 µM, prostaglandin E2 (PGE2) and IL-1 pada dos 12.5 µM dan ke atas serta tumor nekrosi faktor (TNF)- dan IL-6 pada dos 25  $\mu$ M dengan p < 0.05 dalam ujian-ujian I, II and III masing-masing. HMP tidak dapat mempengaruhi penghasilan IL-8 dan monocyte chemotactic protein (MCP)-1 serta sitokin anti-inflamasi (IL-10). Pengurangan NO oleh HMP adalah disebabkan oleh sekatan terhadap rembesan NO dan ekspres iNOS. Melalui western blotting dan ujian kinase dalam ujian III and IV, penyekatan terhadap fosforilasi p38 protein dan juga aktiviti enzim-enzim ini yang akan menghasilkan phospho-ATF2 juga dikurangkan. Kesan-kesan tersebut menyebabkan pula berlakunya halangan terhadap activating protein (AP)-1 aktiviti pengikatan di mana halangan inilah yang menyebabkan pengeluaran NO oleh HMP. HMP tidak berkesan terhadap fosforilasi oleh extracellular-signal-related-kinase (ERK) 1/2 dan Jun N-terminal kinase (JNK) serta activiti-activiti oleh enzim-enzim ini. Selain itu, HMP juga gagal menyekat fosforilasi oleh inhibitory protein κΒ (I-κΒ) ataupun signal transducers and activators of transcription (STAT)-1 dan nuklear translokasi serta DNA binding oleh nuklear faktorκΒ (NF-κΒ) Pengajian molekul docking telah membuktikan bahawa penyekatan p38 oleh HMP adalah secara selektif. Tambahan pula, HMP menunjukkan persamaan dalam pola pengikatan terhadap halaman aktif p38 kinase apabila dibandingkan dengan SB 203580 (p38 inhibitor selektif) tersebut dalam pengajian tersebut. kesimpulannya, keputusan-keputusan ini menunjukkan bahawa tindakan anti-radang oleh HMP adalah lebih selektif, dijangka dapat mengurangkan akibat sampingan jika dibandingkan dengan calkon-calkon yang lain.

#### ACKNOWLEDGEMENTS

First, I would like to express my full gratitude to my project supervisor, Professor Dr. Daud Ahmad Israf Ali, the Chairman of my Supervisory Committee, for his invaluable advice, guidance, constant support and encouragement.

I would like to extend my appreciation to Dr. Kim Min Kyu and my co-supervisors, Professor Dr. Mohd Roslan bin Sulaiman and Associate Professor Dr. Cheah Yoke Kqueen, from the Department of Biomedical Sciences, Faculty of Medicine and Health Sciences for their generous input, constructive criticism, advice and support throughout the course of this study. In addition, I would like thank to my colleagues, all the staff and friends of the cell signaling and molecular biology laboratories, Faculty of Medicine and Health Sciences for their kind, excellent and constant technical assistance.

Subsequently, I would like to extend my thanks and appreciation to Professor Dr Md Nordin Hj Lajis for providing compounds for this research project as well as his student, Lam Kok Wai for conducting the chemical synthesis and docking experiment of the compounds. Last but not least, I would like to express my greatest and innumerous blessing and gratitude to my dearest parents and family members for their sacrifice, moral support and constant love all this time.

I certify that a Thesis Examination Committee has met on date of viva voce to conduct the final examination of Liew Choi Yi on her Master of Science thesis entitled 'Mechanism of anti-inflammatory action of 3-(2-hydroxy-phenyl)-1-(5-methyl-furan-2-y-l) propenone (HMP)' in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded degree of Master of Science.

Members of the Examination Committee were as follows:

#### Mohd Aziz Dollah, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

#### Sharida Fakurazi, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examinar)

# Zainul Amirudin Zakaria, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examinar)

### Ahmad Rohi Ghazali, PhD

Associate Professor
Faculty of Allied Health Sciences
Universiti Kebangsaan Malaysia
(External Examinar)

#### **BUJANG KIM HUAT, PhD**

Professor and Deputy Dean School of Graduate Studies Universiti Putra Malaysia

Date: 19 July 2010

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

# Daud Ahmad bin Israf Ali, PhD

Professor Faculty of Medicine and Health Sciences Universiti Putra Malaysia (Chairman)

# Mohd Roslan bin Sulaiman, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

# Cheah Yoke Kqueen, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

# HASANAH MOHD GHAZALI, PhD

Professor and Dean School of Graduate Studies Universiti Putra Malaysia

Date: 19 July 2010

# **DECLARATION**

I declare that the thesis is my original work except for the synthesis of tested compounds, docking experiment, quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.

LIEW CHOI YI

Date: 19 July 2010

# TABLE OF CONTENTS

ABSTRACT  ABSTRAK  ACKNOWLEDGEMENTS  APPROVAL  DECLARATION  LIST OF TABLES  LIST OF FIGURES  INTRODUCTION  1  2 LITERATURE REVIEW  2.1 Inflammation 2.2 Nitric oxide and inducible nitric oxide synthase 2.3 Prostaglandin and cyclooxygenase-2 2.4 Cytokines 2.5 Proinflammatory Activation Pathways 2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT) 2.5.2 Mitogen-activated protein kinases (MAPKs) 2.5.3 Nuclear factor-κB (NF-κB)  2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone  3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 3.4 Cell treatment 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30 31 31 32 34 35 36 36 36 36 36 36 36 36 36 36 36 36 36				Page		
DECLARATION	ABS	ABSTRAK				
LIST OF TABLES   XIII	API	PROVAL	L	VI		
LIST OF FIGURES   XIII						
CHAPTER						
CHAPTER         1       INTRODUCTION       1         2       LITERATURE REVIEW       6         2.1       Inflammation       6         2.2       Nitric oxide and inducible nitric oxide synthase       8         2.3       Prostaglandin and cyclooxygenase-2       9         2.4       Cytokines       10         2.5       Proinflammatory Activation Pathways       11         2.5       2.5       Proinflammatory Activation Pathways       11         2.5       2.5       Proinflammatory Activation Pathways       11         2.5       2.5       Indicate Proinflammatory and activators of transcription (JAK/STAT)       11         2.5       2.2       Mitogen-activated protein kinases (MAPKs)       12         2.5       3.3       Nuclear factor-κB (NF-κB)       16         2.6       Anti-inflammatory drugs       18         2.6       2.6       Non-steroidal anti-inflammatory drugs (NSAIDs)       19         2.6       3.       Natural anti-inflammatory compounds       22         2.7       Chalcone       23         3       MATERIALS AND METHODS       26         3.1       Media preparation       26         3.2       Cell						
1 INTRODUCTION 1  2 LITERATURE REVIEW 6 2.1 Inflammation 6 2.2 Nitric oxide and inducible nitric oxide synthase 8 2.3 Prostaglandin and cyclooxygenase-2 9 2.4 Cytokines 10 2.5 Proinflammatory Activation Pathways 11 2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT) 11 2.5.2 Mitogen-activated protein kinases (MAPKs) 12 2.5.3 Nuclear factor-κB (NF-κB) 16 2.6 Anti-inflammatory drugs 18 2.6.1 Corticosteroids 18 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 19 2.6.3 Natural anti-inflammatory compounds 22 2.7 Chalcone 23  3 MATERIALS AND METHODS 26 3.1 Media preparation 26 3.2 Cell culture and viability 26 3.3 Cell viability assay 27 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30				21 11		
2 LITERATURE REVIEW 2.1 Inflammation 2.2 Nitric oxide and inducible nitric oxide synthase 2.3 Prostaglandin and cyclooxygenase-2 2.4 Cytokines 2.5 Proinflammatory Activation Pathways 2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT) 11 2.5.2 Mitogen-activated protein kinases (MAPKs) 2.5.3 Nuclear factor-κΒ (NF-κΒ) 16 2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone 23 3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30	CH	APTER				
2 LITERATURE REVIEW 2.1 Inflammation 2.2 Nitric oxide and inducible nitric oxide synthase 2.3 Prostaglandin and cyclooxygenase-2 2.4 Cytokines 2.5 Proinflammatory Activation Pathways 2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT) 11 2.5.2 Mitogen-activated protein kinases (MAPKs) 2.5.3 Nuclear factor-κΒ (NF-κΒ) 16 2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone 23 3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30	1	INTI	RODUCTION	1		
2.1       Inflammation       6         2.2       Nitric oxide and inducible nitric oxide synthase       8         2.3       Prostaglandin and cyclooxygenase-2       9         2.4       Cytokines       10         2.5       Proinflammatory Activation Pathways       11         2.5       Proinflammatory Activation Pathways       11         2.5       Janus kinases/ signal transducers and activators of transcription (JAK/STAT)       11         2.5       Mitogen-activated protein kinases (MAPKs)       12         2.5       Nuclear factor-κΒ (NF-κΒ)       16         2.6       Anti-inflammatory drugs       18         2.6       2.6       Non-steroidal anti-inflammatory drugs (NSAIDs)       19         2.6       3. Natural anti-inflammatory compounds       22         2.7       Chalcone       23         3       MATERIALS AND METHODS       26         3.1       Media preparation       26         3.2       Cell culture and viability       26         3.3       Cell viability assay       27         3.4       Cell treatment       28         3.5       Reverse transcription-polymerase chain reaction (RT-PCR) analysis       29         3.5.1       Ribonucleic acid (	•	11 \ 1 1	LODGE FIGURE	1		
2.2 Nitric oxide and inducible nitric oxide synthase 2.3 Prostaglandin and cyclooxygenase-2 9 2.4 Cytokines 10 2.5 Proinflammatory Activation Pathways 11 2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT) 11 2.5.2 Mitogen-activated protein kinases (MAPKs) 12 2.5.3 Nuclear factor-κB (NF-κB) 16 2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 18 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone 23 3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 2.6 3.3 Cell viability assay 2.7 3.4 Cell treatment 2.8 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 2.9 3.5.1 Ribonucleic acid (RNA) preparation 2.9 3.5.2 Quantitation of RNA 30	2	LITE	ERATURE REVIEW	6		
2.3 Prostaglandin and cyclooxygenase-2 2.4 Cytokines 2.5 Proinflammatory Activation Pathways 2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT) 2.5.2 Mitogen-activated protein kinases (MAPKs) 2.5.3 Nuclear factor-κΒ (NF-κΒ) 16 2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.6.4 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.5 Natural anti-inflammatory compounds 2.6.6 Natural anti-inflammatory compounds 2.6.7 Chalcone 2.7 Chalcone 2.8 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 2.7 Chalcone 2.8 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 2.9 3.5.1 Ribonucleic acid (RNA) preparation 2.9 3.5.2 Quantitation of RNA 30		2.1	Inflammation	6		
2.4       Cytokines       10         2.5       Proinflammatory Activation Pathways       11         2.5.1       Janus kinases/ signal transducers and activators of transcription (JAK/STAT)       11         2.5.2       Mitogen-activated protein kinases (MAPKs)       12         2.5.3       Nuclear factor-κB (NF-κB)       16         2.6       Anti-inflammatory drugs       18         2.6.1       Corticosteroids       18         2.6.2       Non-steroidal anti-inflammatory drugs (NSAIDs)       19         2.6.3       Natural anti-inflammatory compounds       22         2.7       Chalcone       23         3       MATERIALS AND METHODS       26         3.1       Media preparation       26         3.2       Cell culture and viability       26         3.3       Cell viability assay       27         3.4       Cell treatment       28         3.5       Reverse transcription-polymerase chain reaction (RT-PCR) analysis       29         3.5.1       Ribonucleic acid (RNA) preparation       29         3.5.2       Quantitation of RNA       30		2.2	Nitric oxide and inducible nitric oxide synthase	8		
2.5 Proinflammatory Activation Pathways 2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT) 2.5.2 Mitogen-activated protein kinases (MAPKs) 2.5.3 Nuclear factor-κB (NF-κB) 16 2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone 23  3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA			Prostaglandin and cyclooxygenase-2	_		
2.5.1 Janus kinases/ signal transducers and activators of transcription (JAK/STAT)  2.5.2 Mitogen-activated protein kinases (MAPKs)  2.5.3 Nuclear factor-κB (NF-κB)  2.6 Anti-inflammatory drugs  2.6.1 Corticosteroids  2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs)  2.6.3 Natural anti-inflammatory compounds  2.7 Chalcone  3.1 Media preparation  3.2 Cell culture and viability  3.3 Cell viability assay  3.4 Cell treatment  3.5 Reverse transcription-polymerase chain reaction (RT-PCR)  analysis  29  3.5.1 Ribonucleic acid (RNA) preparation  29  3.5.2 Quantitation of RNA		2.4	Cytokines	10		
transcription (JAK/STAT)  2.5.2 Mitogen-activated protein kinases (MAPKs)  2.5.3 Nuclear factor-κB (NF-κB)  16  2.6 Anti-inflammatory drugs  2.6.1 Corticosteroids  2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs)  2.6.3 Natural anti-inflammatory compounds  2.7 Chalcone  3.1 Media preparation  3.2 Cell culture and viability  3.3 Cell viability assay  3.4 Cell treatment  28  3.5 Reverse transcription-polymerase chain reaction (RT-PCR)  analysis  29  3.5.1 Ribonucleic acid (RNA) preparation  29  3.5.2 Quantitation of RNA		2.5		11		
2.5.2 Mitogen-activated protein kinases (MAPKs)  2.5.3 Nuclear factor-κB (NF-κB)  2.6 Anti-inflammatory drugs  2.6.1 Corticosteroids  2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs)  2.6.3 Natural anti-inflammatory compounds  2.7 Chalcone  3.1 Media preparation  3.2 Cell culture and viability  3.3 Cell viability assay  3.4 Cell treatment  3.5 Reverse transcription-polymerase chain reaction (RT-PCR)  analysis  3.5.1 Ribonucleic acid (RNA) preparation  29  3.5.2 Quantitation of RNA  30						
2.5.3 Nuclear factor-kB (NF-kB)  2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone  3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30						
2.6 Anti-inflammatory drugs 2.6.1 Corticosteroids 18 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 22 2.7 Chalcone 23  MATERIALS AND METHODS 3.1 Media preparation 26 3.2 Cell culture and viability 26 3.3 Cell viability assay 27 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30						
2.6.1 Corticosteroids 2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone  3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 3.4 Cell treatment 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30						
2.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone  3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 3.3 Cell viability assay 3.4 Cell treatment 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 3.5.1 Ribonucleic acid (RNA) preparation 2.7 2.7 2.9 2.9 3.5.1 Ribonucleic acid (RNA) preparation 2.8 2.9 3.5.2 Quantitation of RNA		2.6				
2.6.3 Natural anti-inflammatory compounds 2.7 Chalcone  3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 26 3.3 Cell viability assay 27 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30						
2.7 Chalcone 23  MATERIALS AND METHODS 26 3.1 Media preparation 26 3.2 Cell culture and viability 26 3.3 Cell viability assay 27 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30						
3 MATERIALS AND METHODS 3.1 Media preparation 3.2 Cell culture and viability 26 3.3 Cell viability assay 27 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30		2.7	5 1			
3.1 Media preparation  3.2 Cell culture and viability  3.3 Cell viability assay  3.4 Cell treatment  3.5 Reverse transcription-polymerase chain reaction (RT-PCR)  analysis  29  3.5.1 Ribonucleic acid (RNA) preparation  29  3.5.2 Quantitation of RNA  30		2.1	Chalcone	23		
3.2 Cell culture and viability 26 3.3 Cell viability assay 27 3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30	3	MAT	TERIALS AND METHODS	26		
3.3 Cell viability assay  3.4 Cell treatment  3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis  3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30		3.1	Media preparation	26		
3.4 Cell treatment 28 3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30		3.2	Cell culture and viability	26		
3.5 Reverse transcription-polymerase chain reaction (RT-PCR) analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30		3.3	Cell viability assay	27		
analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30		3.4	Cell treatment	28		
analysis 29 3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30		3.5	Reverse transcription-polymerase chain reaction (RT-PCR)			
3.5.1 Ribonucleic acid (RNA) preparation 29 3.5.2 Quantitation of RNA 30				29		
3.5.2 Quantitation of RNA 30			•	29		
			3.5.3 RNA integrity check	30		

	3.5.4	RT-PCR	31	
	3.5.5	Electrophoresis	31	
3.6	Western Blot Analysis			
	3.6.1	Protein preparation	32	
	3.6.2	Preparation of the whole cell extract	33	
	3.6.3	Preparation of nuclear and cytoplasmic fractions	34	
	3.6.4	Determination of protein concentration	34	
	3.6.5	Preparation for sodium-dodecyl sulphate polyacrylamide		
		gel electrophoresis (SDS-PAGE)	35	
	3.6.6	Gel electrophoresis	35	
	3.6.7	Gel staining and destaining	36	
	3.6.8	Semi-dry protein transfer	36	
	3.6.9	Membrane staining	37	
	3.6.10	Immunoblotting	37	
	3.6.11	Visualisation	38	
3.7	Immu	nopreci <mark>pitati</mark> on a <mark>nd kin</mark> ase assay	38	
	3.7.1	Preparation of cell lysates	39	
	3.7.2	Immunoprecipitation with immobilized antibodies	39	
	3.7.3	Kinase assay	39	
	3.7.4	Immunoblotting	40	
3.8	Electrophoretic mobility shift assay (EMSA)			
	3.8.1	Preparation of cell lysates	41	
	3.8.2	Oligonucleotide labeling	41	
	3.8.3	Gel shift Assay	42	
3.9	Study	I: Nitrite secretion assay	43	
3.10	Study	I: iNOS activity assay	44	
3.11	Study	I: Nitrite scavenging activity assay	45	
3.12	Study	I: iNOS mRNA expression analysis	46	
3.13	Study	I: iNOS protein expression analysis	46	
3.14	Study	II: PGE2 secretion assay	47	
3.15	Study	II: COX-2 activity assay	48	
3.16	Study II: COX-2 mRNA expression analysis			
3.17	Study II: COX-2 protein expression analysis			
3.18	Study	III: Cytokine secretion determination	49	
3.19	Study	III: Proinflammatory cytokines (TNF- $\!\alpha$ and IL-1 $\!\beta\!$ ) mRNA		
		expression analysis	50	
3.20	Study	IV: MAPKs protein expression analysis	50	
3.21	Study	IV: MAPKs activity assay	51	
3.22	Study	IV: I-κB expression analysis	52	
3 23	Study	IV: p65 NF-kB expression analysis	53	

	3.24	Study IV: STAT1 expression analysis	53			
	3.25	Study IV: NF-κB and AP-1 DNA binding activity assay	54			
	3.26	Study IV: Docking experiment	54			
	3.27	Statistical analysis	55			
4	RESULTS					
	4.1	Effect of HMP on cell viability of RAW264.7 and U937 cells	56			
	4.2	Study I: Effect of HMP on NO secretion	58			
	4.3	Study I: Effect of HMP on iNOS enzyme activity	60			
	4.4	Study I: Scavenging activity of HMP	61			
	4.5	Study I: Effect of HMP on mRNA level of iNOS gene	62			
	4.6	Study I: Effect of HMP on iNOS protein expression	63			
	4.7	Study II: Effect of HMP on PGE2 secretion	64			
	4.8	Study II: Effect of HMP on COX-2 enzymatic activity	65			
	4.9	Study II: Effect of HMP on COX-2 gene expression	66			
	4.10	Study II: Effect of HMP on COX-2 protein expression	67			
	4.11	Study III: Effect of HMP on proinflammatory cytokine and				
		chemokines secretion	68			
	4.12	Study III: Effect of HMP on proinflammatory cytokines mRNA				
		(TNF-α and IL-1β)	71			
	4.13	Study IV: Effect of HMP on activation of MAPKs in				
		RAW 264.7 cells	72			
	4.14	Study IV: Effect of HMP on p38 activity	76			
	4.15	Study IV: Effect of HMP on phosphorylation and				
		degradation of I-κBα	78			
	4.16	Study IV: Effect of HMP upon the IFN-γ/LPS-induced levels of	<b>7</b> 0			
	4.17	p65 into the nucleus	79			
	4.17	Study IV: Effect of HMP on phosphorylation of STAT	81			
	4.18	Study IV: Effect of HMP on NF-kB and AP-1 DNA binding	00			
	4.10	activity  Study IV: Decking Studies of HMD years 220 kinese	82			
	4.19	Study IV: Docking Studies of HMP upon p38 kinase	83			
5	DISCUSSION					
6	CON	CLUSION	96			
	REFERENCES APPENDICES BIODATA OF STUDENT					
	BIODATA OF STUDENT					
LIST	LIST OF PUBLICATIONS					